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The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections.
With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of
lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may
havesigniﬁcantimpactonpatientmanagement.Thisreviewprovidesanoverviewofancillarytestscurrentlyusedinthepathologic
diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics.
1.Introduction
Primary lung cancer has been classiﬁed historically into two
clinically relevant groups: small cell lung cancer (SCLC)
and nonsmall cell lung cancer (NSCLC). This distinction
was clinically useful as available treatment strategies diﬀered
signiﬁcantly between these two groups. In recent years, the
emerging evidence of diﬀerential response to new targeted
therapies and the identiﬁcation of molecular diﬀerences
between speciﬁc subtypes of NSCLC increasingly necessitate
greater accuracy in the subtyping of NSCLC.
The current WHO classiﬁcation of lung cancer [1]h a s
been based almost entirely by assessment of morphologic
features using standard hematoxylin and eosin (H&E)
stained sections of tumors. However, a growing number of
ancillary studies can help with classiﬁcation, such as the
use of immunohistochemistry (IHC). Beyond simple classi-
ﬁcation, however, ancillary testing for molecular aberrations
is entering routine practice and delivers additional prog-
nostic and predictive information. A new multidisciplinary
classiﬁcation system for primary lung adenocarcinomas has
emerged recently [2]. While this system is still based largely
on morphology, it moves towards incorporating recent
advances in clinical and molecular medicine. In this review,
wesummarizeancillarytestscurrentlyusedinthepathologic
diagnosisoflungcancer,withafocusonimmunohistochem-
istry and molecular diagnostics.
2. Immunohistochemistry
Immunohistochemistry involves the detection and localiza-
tionofantigensorproteinsintissuesectionsbytheuseofan-
tibodies that bind speciﬁcally to the antigen of interest. The
antibodies are coupled to a detection system which allows
them to be visualized in tissue sections. IHC has a range of
applications in the practice of pathology and is commonly
used by pathologists to help in distinguishing cell types or
their origin, using markers that are expressed diﬀerentially
between diﬀerent cell types and organs. Additionally, IHC
enables one to observe or determine the localization and dis-
tribution of various antigens or proteins within the tissue.
However, it needs to be recognized that IHC is neither
100% speciﬁc nor 100% sensitive. For example, thyroid tran-
scription factor-1 (TTF-1) is widely known as a marker for
pulmonary adenocarcinoma but is also highly expressed in2 Pulmonary Medicine
Table 1: Immunohistochemical proﬁles of squamous cell carci-
noma and pulmonary adenocarcinoma.





thyroid tumors and may uncommonly also be expressed in
carcinomas originating from other primary sites, including,
for example, colorectal carcinoma [3]. Morphologic features
on H&E sections remain the basis for diagnosis, and
ancillary tests need to be interpreted in the context of the
histomorphologic ﬁndings. Despite these limitations, it has
been shown that a high degree of accuracy in the subtyping
of NSCLC can be achieved by applying a simple panel
of immunohistochemical markers including TTF-1, tumor
protein 63 (P63), cytokeratin (CK) 7, and CK5/6 [4, 5].
Other antibodies such as desmocollin-3 and napsin A have
also been recently described as helpful in further reﬁning the
subtypes in diﬃcult cases [6, 7].
CKs are intermediate ﬁlament proteins that provide
structural support within the cytoplasm of epithelial cells.
Fifty-four CK genes have been identiﬁed, and the corre-
sponding keratin proteins are classiﬁed by molecular weight
and isoelectric pH [8]. In the most general terms, tumors of
epithelial origin (termed carcinomas or adenocarcinomas, if
gland forming) express CKs, which diﬀerentiates them from
tumors of mesenchymal origin (sarcomas), hematopoietic
origin (lymphomas/leukemias), and melanoma. The various
epithelial tissues of the human body also express diﬀerent
CKs, thus diﬀerent epithelial tumors may often be distin-
guishedbasedontheiruniquecytokeratinexpressionproﬁle.
TTF-1 plays an important role in the embryogenesis of
lung, and its expression remains high in type II pneumocytes
and Clara cells [9]. TTF-1 has been used as an immunohisto-
chemical marker for primary lung adenocarcinoma, despite
recent reports of occasional aberrant TTF-1 staining in
tumors from other primary sites (e.g., [3]). TTF-1 is known
to regulate the expression of several lung-speciﬁc proteins
includingnapsinA,surfactantproteins,andothers.Antibod-
ies to napsin A in combination with TTF-1 have been pro-
posedasadditionalevidenceofpulmonaryoriginofatumor.
2.1. Squamous Cell Carcinoma. In H&E stained sections,
squamous diﬀerentiation is identiﬁed by keratinisation
and/or formation of intercellular bridges. Both features are
speciﬁc for squamous cell diﬀerentiation and are not seen in
other tumor types. While these features are readily observed
in well-diﬀerentiated tumors, they may be diﬃcult to appre-
ciate or absent in poorly diﬀerentiated tumors, especially in
small biopsy samples or ﬁne needle aspirate cytology spec-
imens. In such cases, an IHC panel including P63, CK5/6,
TTF-1, and CK7 may be helpful, with positive staining for
P63 and CK5/6 and concurrent lack of staining for TTF-1
and CK7 supporting squamous diﬀerentiation (Table 1)[ 5].
From a clinical standpoint, it is important to note that
squamous diﬀerentiation is not evidence of the tumor’s site
of origin. Metastatic squamous cell tumors to the lung are
histologically and immunohistochemically identical to pri-
mary lung squamous tumors. At present, there are no im-
munohistochemicalormolecularmarkersinroutineusethat
reliably diﬀerentiate primary pulmonary from metastatic
squamous cell carcinomas, as TTF-1 typically is not ex-
pressed in pulmonary squamous cell carcinomas. Therefore,
clinical history is crucial to determining the site of origin.
The accurate diagnosis of squamous cell histology has
important therapeutic implications. Certain systemic ther-
apy agents are not used in patients with squamous histology
for safety or eﬃcacy concerns. Bevacizumab, a monoclonal
antibody directed against vascular endothelial growth factor
(VEGF)isassociatedwithanincreasedriskoflifethreatening
pulmonary hemorrhage in patients with squamous cell his-
tology [10]. The association between bleeding complications
and this histological type has been seen with other VEGF in-
hibitors although not all [11, 12]. Also, pemetrexed, a
chemotherapeutic agent has been associated with inferior
outcomes compared with docetaxel chemotherapy. By con-
trast, pemetrexed use in the ﬁrst-, second-line, and main-
tenance settings has been associated with superior outcomes
inpatientswithnonsquamoushistology[13,14].Thesestud-
ies conﬁrm that accurate classiﬁcation of NSCLC has an im-
portant role in patient management and outcomes.
2.2. Adenocarcinoma. The WHO classiﬁcation [1]o fl u n g
tumors has long divided adenocarcinomas primarily into
acinar, papillary, solid, bronchioloalveolar (BAC), or mixed
subtypes based on histomorphologic features. Classically,
adenocarcinomasdisplayglandformationonH&E,although
subtypes with bronchioloalveolar or solid patterns of growth
maylackwell-deﬁnedglandularstructures.TheBACsubtype
(oradenocarcinomainsitu(AIS)inthenewIASLC/ATS/ERS
classiﬁcation [2]) is characterized by exclusively “lepidic”
growth pattern, in which neoplastic cells grow along the
surfaces of preexisting alveolar structures, without evidence
of invasion. Two variants of BAC have been recognized clas-
sically, mucinous and nonmucinous. The mucinous variant
(mucinous AIS or invasive mucinous adenocarcinoma in
the IASLC/ATS/ERS classiﬁcation [2]) is composed of tall
columnar cells with abundant pale cytoplasm that stains
positively with histochemical stains for mucin, such as muci-
carmine or periodic acid Schiﬀ (PAS). Pulmonary adenocar-
cinoma is diﬀerentiated from squamous cell carcinoma by
being typically positive for CK7 and TTF-1, and negative
for p63 and CK5/6 (Figure 1). Although most pulmonary
adenocarcinomas are positive for TTF-1, a signiﬁcant subset
is negative (15–30%), especially the mucinous BAC subtype,
or those originating in more central locations [15].
Primary lung adenocarcinoma must also be diﬀerenti-
ated from adenocarcinoma that has metastasized to lung.
Clinical history and IHC can be invaluable in this regard.
In particular, the diﬀerential expression of CK7 and CK20
may be very useful in characterizing the origin of epithe-
lial neoplasms. Pulmonary adenocarcinoma is typically
CK7+/CK20− by IHC although this cytokeratin proﬁle isPulmonary Medicine 3






Figure 1: Immunohistochemistry stains in squamous cell carcinoma and adenocarcinoma of lung. H&E: hematoxylin and eosin; CK:
cytokeratin; TTF-1: thyroid transcription factor 1. Squamous carcinomas are typically positive for CK5/6 and P63, and negative for CK7 and
TTF-1,withthereverseproﬁleforadenocarcinomaalthoughthiscaseofsquamouscellcarcinomademonstratesfocalweakstainingforCK7.
not speciﬁc to adenocarcinomas of lung and may be seen
also in tumors arising from the breast, thyroid, upper gastro-
intestinal and pancreaticobiliary tracts, and gynecologic
tract. Tumors demonstrating CK7−/CK20+ staining proﬁle
includecolorectalandMerkelcellcarcinomas.CK20staining
may occasionally be seen in pulmonary adenocarcinomas,
but CK7 typically is also positive in such cases. While an ex-
haustive discussion is beyond the scope of this manuscript,
suﬃce to indicate that most primary lung adenocarcinomas
are CK7 and TTF-1 positive, although as previously noted,
TTF-1 staining may also be seen in thyroid tumors and infre-
quently in tumors originating from other body sites. Lack of
TTF-1 expression does not exclude pulmonary origin for a
CK7-positive adenocarcinoma in the lung; however, in this
situation, metastatic carcinoma arising from other body sites
that demonstrate a CK7+/CK20− cytokeratin proﬁle would
need to be excluded clinically.
Napsin A, an aspartic acid protease whose expression in
the lung is regulated by TTF-1, has also shown promise in
helping to diﬀerentiate primary lung from metastatic adeno-
carcinomas. While napsin A expression may also be seen in
normal kidney and in a proportion of renal tumors, positivi-
ty for both TTF-1 and napsin A is a strong indication that an
adenocarcinoma originated from lung [6, 16].
2.3. Neuroendocrine Tumors. Tumors with neuroendocrine
(NE) diﬀerentiation include small cell carcinoma, large
cell neuroendocrine carcinoma, and typical and atypical4 Pulmonary Medicine
Table 2: Immunohistochemical proﬁle of neuroendocrine tumors.
IHC Typical carcinoid Atypical carcinoid Primary lung small cell ca. Metastatic small cell ca.
CD56 + + + +
Synaptophysin + + +/− +/−
Chromogranin + + −/+ −/+
TTF-1 −/+ −/+ Usually + Usually −
Ki-67 0–5% 5–15% >20% (typically >60%) >20% (typically >60%)
carcinoidtumors.NEtumorsaredeﬁnedultrastructurallyby
havingneurosecretorygranulesandimmunohistochemically
b yp o s i t i v i t yf o rN Em a r k e r s( Table 2). According to a
recent international workshop on pulmonary NE tumors,
CD56 has a sensitivity of 95% and a speciﬁcity of 97% for
detecting cells showing NE diﬀerentiation. The sensitivity
for synaptophysin and chromogranin is 80–85%, and the
speciﬁcity for both is 97% [17]. Using a panel of two or three
NE markers ensures a high degree of accuracy for detecting
NE diﬀerentiation.
Diﬀerentiating between the diﬀerent types of NE tumors
m a yb ev e r yd i ﬃcult in small biopsy specimens because the
small sample may not be entirely representative of the overall
tumor and is subject to crush artefact because of the relative
fragility of these cells. In some cases, the evaluation of Ki-
67 may be useful in this regard. Ki-67 is a marker of cell
proliferation, and a recent review has concluded that the
Ki-67 proliferation index of typical carcinoid (TC) is less
than 2%, while atypical carcinoid (AC) is less than 20%
(typically around 10%) [18]. Small cell carcinomas often
have a Ki-67 proliferation index of greater than 60%. It has
been suggested that a Ki-67 index of less than 25% excludes
small cell carcinoma [19].
Diﬀerentiating primary NE tumors of the lung from NE
tumors from other body sites may also be a challenge, as
NE tumors arising from other body sites may demonstrate
identical morphology. In this regard, expression of TTF-1
maybehelpfultoidentifyacarcinoidtumoroflungorigin,as
carcinoid tumors from other sites rarely express this marker
[20]. However, small cell carcinomas arising from the lung
frequently express TTF-1 while those arising from other sites
may occasionally also express TTF-1. In the case of small cell
carcinoma with TTF-1 positivity, lung origin is favored, but
t h i si sn o te n t i r e l yd e ﬁ n i t i v e[ 21].
2.4. Other IHC Markers
P53. P53 functions as a tumor suppressor protein by playing
a key role in cell cycle progression, apoptosis, and DNA
repair [22]. Overexpression of P53 in NSCLC has been
reported to be both a prognostic marker, associated with in-
creased tumor aggressiveness and shorter overall survival,
and a potential predictive marker, associated with a favorable
response to platinum-based adjuvant chemotherapy, result-
ing in a survival beneﬁt [23]. However, this needs additional
validation.
ASH1. From an embryologic perspective, there is now evi-
dencethatthetranscriptionfactorachaete-scutehomologue-
1 (ASH1) is pivotal for NE cell diﬀerentiation and may be
necessary for transformation to NE lung carcinoma [24].
Immunohistochemical analysis of ASH1 is available but not
routinely used outside of the research setting at present. It
may potentially help to identify early progenitor cells that are
committed to NE diﬀerentiation and better deﬁne subsets of
lung cancers demonstrating NE diﬀerentiation [24].
3.MolecularDiagnosticsinNSCLC
Molecular testing of lung cancers has seen signiﬁcant advan-
ces in recent years. The potential information derived from
molecular tests is enormous and has increasing applications
in clinical settings. In the setting of lung cancer, molecular
techniques currently employed include both polymerase
chain reaction- (PCR) based tests and ﬂuorescent in-situ hy-
bridization (FISH). Both of these tests can be done using for-
malin-ﬁxed-paraﬃn-embedded (FFPE) tissue provided that
there is suﬃcient tumor quantity and a nondegraded spec-
imen. PCR is a molecular technique used to amplify short
segments of DNA. The ampliﬁed DNA from tumor samples
can then be subject to various analyses to identify diﬀerences
(mutations) from a “normal” control. FISH is a technique
whereby ﬂuorescent labeled probes are admixed with a test
sample and the probes bind to speciﬁc DNA sequences if
present.Fluorescentmicroscopyisthenusedtoanalyzeifand
where on the chromosomes the probes have bound. Probes
can be designed to bind either normal segments of DNA or
segments with known aberrations. A brief review of selected
genetic abnormalities with clinical relevance in lung cancer
follows (summarized in Table 3). A more extensive review
of molecular predictive and prognostic markers has been
published elsewhere [25].
3.1. Epidermal Growth Factor Receptor (EGFR). EGFR repre-
sents a family of transmembrane tyrosine kinase growth fac-
tor receptors involved in a wide array of cellular processes,
including proliferation, apoptosis, angiogenesis, and others.
A number of patients with NSCLC have dysregulated EGFR
resultinginoverexpression,ampliﬁcation,ormutations[26].
Clinical and pathological features associated with high-fre-
quency mutations in the EGFR tyrosine kinase (TK) do-
main in NSCLC include East Asian ethnicity, females,
light/never smokers, and tumors with adenocarcinoma his-
tology. In the general North American or European popula-
tion,approximately10–17%ofNSCLCcasesmayhaveEGFRPulmonary Medicine 5
Table 3: Clinically relevant molecular and clinicopathologic features of NSCLC.
EGFR mutation K-ras mutation EML4-ALK mutation
Histologic subtype Adenocarcinoma NSCLC (Adeno > squamous) Adenocarcinoma, signet ring
morphology
Clinical features Asian, female, light/never smokers Past or present smokers Light/never smokers, possible
young age and male
Signiﬁcance Sensitive to EGFR TKI therapy
Relative resistance to EGFR TKI
therapy, possible poor prognostic
marker
Use of ALK inhibitors
(currently under study)
mutations [27]. In light or never-smoking Asian patients
with adenocarcinoma, the rate of EGFR mutations may
be as high as 60% [28]. Mutated EGFR predicts for high
response rate to EGFR TK inhibitor (TKI) therapy, a ﬁrst-
line treatment choice in advanced NSCLC patient popula-
tion [29], with better progression-free survival and quality
of life. Accurate mutation analysis is also important because
progression-free survival is shorter if EGFR wild-type pa-
tients are treated with EGFR TKIs as opposed to convention-
al chemotherapy. There is also evidence that diﬀerent muta-
tions may have diﬀerential response rates and relative resist-
ance to EGFR TKI’s [30].
Aberrations in EGFR are common in a wide variety of
human cancers, but the site of mutation varies with the type
of malignancy. Activating mutations in EGFR result in con-
stitutively activated downstream signalling pathways. Studies
onEGFRmutationsinNSCLCshowthatapproximately90%
occur within exons 18–21 [31]. The speciﬁc type of mutation
may hold predictive relevance in that some mutations confer
higher aﬃnity for certain EGFR TKIs and some confer
resistance to certain EGFR TKIs, for example, mutations
in exon 20 and the T790M mutation. Various diﬀerent
methods are currently used for the detection of EGFR
mutations (reviewed in [32]). Of these, direct sequencing of
PCR amplicons from the EGFR gene is perhaps the most
widely used but is also cost and labor intensive. Targeted
detection of speciﬁc mutations is also an option, given that
two mutations account for more than 90% of all EGFR
mutations in NSCLC (exon 19 deletions and the exon 21
L858R mutation) [33]. However, the development of mon-
oclonal antibodies directed against the two most common
mutations may enable immunohistochemical screening for
EGFR mutations, providing rapid results at a fraction of the
cost of current molecular testing [34].
3.2. K-RAS. The ras family of oncogenes encode for proteins
that mediate signalling pathways controlling cell growth.
There are three distinct ras genes (H-ras,K - ras,N - ras), each
of which has been associated with various malignancies.
In NSCLC, >90% of ras mutations occur on the K-ras
gene, which would result in the constitutive activation of
downstream signalling pathways. K-ras mutations are seen
almost exclusively in smokers, and this relationship does not
seem to be dose or time dependent [35]. K-ras mutations
in NSCLC occur mainly in adenocarcinoma. As a prognostic
marker, K-ras mutation appears to be associated weakly with
pooreroutcome[36].K-rasmutationsrarelyoccurintumors
with EGFR mutations. Their presence has been associated
with relative resistance to EGFR TKI therapy [37] although
currently patients with K-ras mutations are not excluded
from EGFR TKI therapy. In the rare patient that has both
aK - ras mutation and an activating EGFR mutation, EGFR
TKI therapy may be appropriate [38, 39].
3.3. EML4-ALK. The anaplastic lymphoma kinase (ALK)
gene was originally identiﬁed as part of a chromosomal
translocation found in a subset of anaplastic large cell
lymphomas. Subsequently, it has been shown that ALK
is dysregulated in a number of solid and hematologic
malignancies. The mechanisms of dysregulation include
translocations as well as mutations in the tyrosine kinase
domain [40]. In 2007, a translocation between echinoderm
microtubule-associated protein-like 4 (EML4) and ALK was
identiﬁed in a subset of lung adenocarcinomas [41]. The
fusion product has oncogenic properties, and transgenic
mice that express EML4-ALK in alveoli develop hundreds of
nodules of adenocarcinoma [42].
The result of an early-phase trial with crizotinib, an
inhibitor developed for ALK and Met, has generated con-
siderable interest as a therapeutic option in patients with
NSCLC who harbor EML4-ALK mutations [43] ;an u m b e r
of clinical trials are currently underway to determine their
eﬃcacy and parameters for optimal use.
The overall incidence of EML4-ALK rearrangements
in NSCLC appears to be approximately 3.5% [44]. There
appears to be a similar frequency of ALK mutations across
diﬀerent ethnicities, suggesting that race may not be as rele-
vant as for EGFR mutations. Clinical parameters associated
with ALK mutations include never/light smokers, and in
some studies there is an association with younger patient
age and male sex [45, 46]. From a histologic perspective,
EML4-ALK rearrangement is seen almost exclusively in
adenocarcinomas, and only rare cases have been reported
in squamous cell carcinoma [41, 46]. Interestingly, signet
ring cell histology has been associated frequently with ALK
rearranged tumors [45].
A variety of techniques are available to detect ALK
gene rearrangements including FISH, IHC, and PCR. FISH
probes that identify ALK rearrangements are commonly
used in clinical trials. The limitation of this method is
that the translocation can be diﬃcult to detect due to the
small size of the inversion [47]. Attempts to use IHC to
detect ALK-rearranged tumors initially met with limited
success as the fusion protein is expressed at low levels;6 Pulmonary Medicine
the development of novel speciﬁc and sensitive antibodies,
however, seems on the horizon [48]. PCR-based techniques
have not gained widespread use as PCR-based detection of
the fusion transcript is generally not optimal in FFPE tissue.
The optimal method for identifying EML4-ALK fusion is yet
to be deﬁnitively determined [49] although FISH is widely
viewed as the current gold standard.
3.4. MET. MET is a receptor tyrosine kinase involved in im-
portantsignallingpathwaysrelatedtocellproliferation,angi-
ogenesis, and tumor aggression [50]. MET signalling be-
comes dysregulated in both NSCLC and small cell lung can-
cer through various mechanisms, including overexpression,
mutations, ampliﬁcations, and autocrine/paracrine activa-
tion of hepatocyte growth factor [51]. MET gene ampliﬁca-
tion as detected by ﬂuorescence in situ hybridization may be
ap o o rp r o g n o s t i cf a c t o ri nN S C L C[ 52]. MET ampliﬁcation
has also been implicated as one mechanism for acquired
resistance to EGFR TKI therapy and may be seen in 5 to 20%
of resistant cases [53, 54]. As a therapeutic option, MET in-
hibitors alone or in combination with EGFR TKIs are in
clinical trials.
4. Conclusion
Clinical, pathological, and genetic parameters are beginning
to converge in NSCLC. Selection of patients based on clinical
and histopathologic criteria can, for example, considerably
increase the likelihood of identifying EML4-ALK and EGFR
mutations. In addition, the development of treatment proto-
cols directed at speciﬁc molecularly or histologically deﬁned
subsets of NSCLC has improved treatment outcomes for
patients. The role of the pathologist is now to provide not
onlyaccuratesubtypingoflungcancers,butincreasinglyalso
to provide prognostic and predictive information that is crit-
ical to patient outcomes. Future developments will continue
to reﬁne our understanding and approach to lung cancer.
Several lung cancer studies have used microarray platforms
to measure the expression of thousands of genes simultane-
ously. The results generated provide unique gene-expression
proﬁles with signiﬁcant prognostic and predictive impact
[55, 56]. Gene expression proﬁling may also help reﬁne
tumor classiﬁcation. While these and other molecular pro-
ﬁling strategies need further validation in prospective stud-
ies, currently available technology points to a future where
the molecular proﬁling will increasingly help guide classiﬁ-
cation, treatment, and prognosis of lung cancers.
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